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ABSTRACT 
Continuous Pharmaceutical Manufacturing (CPM) can revolutionise industrial efficiency via potential 
operational and economic benefits over currently dominant batch methods. Process modelling and 
optimisation are valuable towards rapid design space evaluation and elucidation of optimal process 
design configurations, without expensive and time-consuming experimental campaigns. This paper 
pursues total cost minimisation via nonlinear optimisation of different separation design options for 
atropine, a product of great societal importance. The study considers a demonstrated continuous flow 
synthesis, presents reaction kinetic parameter estimation towards reactor design, and illustrates a 
comparative analysis of the subsequent batch vs. continuous Liquid-Liquid Extraction (LLE) for 
product purification, using published partition coefficient data and UNIFAC-modelled ternary liquid-
liquid equilibria. Original optimisation results show that toluene is the best continuous LLE solvent, 
attaining the lowest total costs at both plant capacities considered and the greatest total cost savings 
with respect to batch LLE design for varying solvent recovery, at acceptable material efficiencies. 
 
1 
1. Introduction 
The pharmaceutical industry produces a wide variety of products whose active pharmaceutical 
ingredients (APIs) often have complex molecular structures, requiring multistep syntheses (Baumann 
and Baxendale, 2015) and stringent product purities set by regulatory bodies (Eger and Mahlich, 
2014). Such requirements imply materially-intensive manufacturing processes, which can also be very 
wasteful and have low operational asset efficiencies (Henderson et al., 2011; Anderson, 2012). 
Consequently, pharmaceutical R&D costs have been historically increasing (DiMasi, Grabowski and 
Hansen, 2016), characterised by fewer new therapeutic discoveries per R&D expenditure (Plenge, 
2016). While total pharmaceutical sales in Europe have been historically increasing, R&D 
expenditures remain high; in the UK, pharmaceutical R&D has been the highest of all manufacturing 
sectors for several years, representing nearly 25% of the total national R&D expenditure (Fig. 1). 
Additionally, competition from generics manufacturers has been historically increasing and is 
predicted to continue (Fig. 2), presenting a threat to pharmaceutical firm profitability. Manufacturing 
costs represent a significant portion of expenditures; thus, improved process efficiencies will have 
significant economic benefits (Rantanen and Khinast, 2015). 
 
 
Figure 1: European pharma R&D expenditures and total sales and UK pharmaceutical manufacturing 
R&D trends by sector (Iervolino, 2016; UK Office for National Statistics, 2016; EFPIA, 2018). 
 
Continuous pharmaceutical manufacturing (CPM) is a new production paradigm for the 
pharmaceutical industry with the potential to revolutionise production by offering enhanced yields, 
purities, heat and mass transfer and mixing efficiencies, reduced waste and lower total costs (Jolliffe 
and Gerogiorgis, 2016; Dallinger and Kappe, 2017). While traditional batch methods have been 
historically implemented for their advantages of equipment flexibility, product recall ability, utility 
for rapid synthetic pathway discovery and having established, well-understood technology, batch 
techniques imply significant waste and low operational asset efficiency, leading to a lack of 
robustness and flexibility which has lead to drug shortages, presenting a threat to public health (Lee et 
al., 2015; Yu and Kopcha, 2017). Despite numerous demonstrations of continuous flow synthetic 
routes towards APIs (Britton et al., 2017; Plutschack et al., 2017), including pilot plant 
demonstrations (Mascia et al., 2013; Adamo et al., 2016; Cole et al., 2017) and industrial scale 
applications (GSK, 2015; Kuehn, 2015) and receiving approval from regulatory bodies (Poechlauer et 
al., 2013), there is wide-scale reluctance to adopt CPM over current batch methods due to significant 
investments in existing infrastructures (Federsel, 2013). Furthermore, development and integration of 
robust continuous separation technologies as part of end-to-end campaigns is essential for successful 
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CPM implementation (Baxendale et al., 2015). Demonstration of feasible and viable CPM processes 
is essential to maintain sustainable pharmaceutical manufacturing practices. 
 
 
Figure 2: Increasing global generics prescription drug revenues (EvaluatePharma, 2018). 
 
Successful CPM implementation requires the selection of viable candidate APIs whose continuous 
flow synthesis has been demonstrated in the literature for CPM application. Atropine is a World 
Health Organisation (WHO) essential medicine, primarily used for the treatment of the effects of 
nerve agents and poisons, often being the most readily available patient treatment in warzones where 
chemical warfare is used (Marrs and Rice, 2016). Atropine is also used to induce cycloplegia and 
mydriasis for ophthalmic treatments, for the treatment of bradycardia and to inhibit salivary and 
mucus glands during medical procedures (Field et al., 2010). The continuous flow synthesis of 
atropine was recently demonstrated, featuring two plug flow reactor (PFRs) followed by a purification 
via liquid-liquid extraction (LLE), partitioning structurally similar impurities between organic and 
aqueous product phases of a multiphase mixture (Bédard et al., 2016); the study showed an improved 
material efficiency over previous demonstrations (Dai et al., 2015). Systematic comparative 
evaluation of process alternatives for operational feasibility and economic viability for atropine CPM 
has yet to be conducted and can elucidate designs of improved economic viability. 
Process modelling, simulation and optimisation is a valid method for rapid systematic comparative 
evaluation of design alternatives prior to significant financial investments in pilot plant studies (Poku 
et al., 2004; Angelopoulos et al., 2014; Teoh, Rathi and Sharratt, 2015; Bana et al., 2017). Theoretical 
methods have been widely implemented in the plantwide design and optimisation of pharmaceutical 
manufacturing processes to elucidate optimal designs (Rogers and Ierapetritou, 2014; Sahlodin and 
Barton, 2015; Escotet-Espinoza, Rogers and Ierapetritou, 2016; Patrascu and Barton, 2018). 
Significant efforts in modelling and simulation in pursuit of continuous pharmaceutical separation 
process development have been demonstrated in recent years. Implementation of combined 
experimental and modelling approaches towards integrated LLE design in the literature for 
pharmaceutical purifications and separations demonstrate the utility of theoretical methods in 
establishing optimal design and operating parameters (Drageset and Bjørsvik, 2016; Monbaliu et al., 
2016; Weeranoppanant et al., 2017). Mathematical optimisation can be used to identify cost optimal 
process designs for pharmaceutical manufacturing campaigns (Gross and Roosen, 1998; Patrascu and 
Barton, 2018); plantwide modelling and optimisation with a focus on optimal continuous separation 
process design towards total cost minimisation have been implemented by our group for numerous 
APIs (Jolliffe and Gerogiorgis, 2017a,b; Diab and Gerogiorgis, 2018b). Elucidating cost-optimal 
designs for atropine CPM will further aid process development for this societally-important API. 
This work develops a process model for total cost minimisation via nonlinear optimisation of the 
CPM of atropine based upon the most recently published continuous flow synthesis (Bédard et al., 
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2016). The design and optimisation of multiphase flow systems to ensure high performance bears 
exceptional importance for many industries (Grujicic and Chittajallu, 2004); beyond first-principles 
approaches, statistical methods are useful towards closure (Ma et al., 2015; Tryggvason et al., 2016).  
Kinetic parameter estimation from published experimental data is implemented for the design of 
PFRs. The experimentally demonstrated batch LLE is compared to a conceptual continuous LLE for 
the purification of the PFR effluent, for which LLE model development and plantwide design 
variation considerations are described. Methods for cost estimation for pharmaceutical processes from 
the literature are then described. The formulation of the constrained nonlinear optimisation problem 
for total cost minimisation of the CPM process is then discussed. Optimal operating and design 
parameters for different process configurations and design assumptions are then provided, with a 
critical discussion of optimisation results, methods and assumptions made. Future work for the 
development of the CPM of atropine are discussed, highlighting the utility of process modelling and 
optimisation studies towards the rapid development of feasible and viable API manufacturing routes. 
2. Process Modelling, Simulation and Optimisation 
2.1 API Continuous Flow Synthesis 
The continuous flow synthesis of atropine is that demonstrated by Bédard et al. (2016). The route 
features three reactions occurring in two PFRs (Fig. 3). The first reactor (PFR-1) features the 
esterification of tropine 2 (in DMF carrier solvent) and phenylacetyl chloride 3 at 100 °C to form 
tropine ester HCl 4 (reaction 1), the free form of which (tropine ester 5) is formed by the addition of 
NaOH. The second reactor (PFR-2) features an aldol addition of formaldehyde (CH2O) to 5 (reaction 
2a) under basic conditions at 100 °C, giving the desired API product. An undesired elimination of API 
to apoatropine 6 (reaction 2b, PFR-2) is also reported (Bédard et al., 2016). 
 
 
Figure 3: Reaction scheme of the demonstrated API continuous flow synthesis (Bédard et al., 2016). 
2.2 Process Flowsheet 
The process flowsheet for atropine CPM considered in this work is shown in Fig. 4; physical 
properties of all materials used in continuous flow syntheses and subsequent separation process 
designs are listed in Table 1. A mixture of 1.0 equiv. tropine 2 (2 M in DMF) and 1.0 equiv. neat 
phenylacetyl chloride 3 undergo esterification at 100 °C in PFR-1. A NaOH solution (1.2 equiv., 3 M 
aq.) is added to the effluent of PFR-1. Formaldehyde is added to the process mixture (6.0 equiv., 37% 
4 
w/v aq.) before entering PFR-2 where the aldol reaction occurs at 100 °C. The batch (BX-) or 
continuous (CPM-) LLE process is operated at TLLE = 25 °C and is further described in section 2.3.3. 
 
Figure 4: Process flowsheet for CPM of atropine (Bédard et al., 2016). 
 
2.3 Process Modelling and Nonlinear Optimisation 
2.3.1 Reaction Performances and Kinetic Parameter Estimation 
Kinetic parameter estimation from available experimental reaction performance data should be 
implemented where possible to gain an understanding of the kinetic behaviour of different reactions 
and for accurate PFR sizing. For the esterification reaction, the published continuous flow synthesis 
reports 99% conversion to 4 at 100 °C in a residence time of 3.5 min (Bédard et al., 2016). As time-
dependent kinetic data is not available for this reaction, this work assumes the same reported 
performance; given the availability of a wider dataset for this reaction, kinetic parameter estimation 
can be performed, which will deepen insight into its kinetic behaviour. 
 
Table 1: Component physical properties. 
Type Component CAS # Formula MW  
(g mol-1) 
m.p. 
(°C) 
b.p.  
(°C) 
ρ  
(g cm-3) 
μ  
(mPa s)
Reagent 
Tropine 2 120-29-6 C8H15NO 141.21    64.0    233.0 1.02 – 
DMF 68-12-2 C3H7NO   73.09   -60.5    153.0 0.95 0.92 
Phenylacetyl chloride 3 103-80-0 C8H7ClO 154.59 –      94.5 1.17 – 
Sodium hydroxide 1310-73-2 NaOH   40.00 318.0 1,388.0 2.13 – 
Water 7732-18-5 H2O   18.02 100.0        0.0 1.00 1.00 
Formaldehyde 50-00-0 CH2O   30.03  -92.0    -19.0 0.82 – 
API 51-55-8 C17H23NO3 289.37 118.5 – 1.21 – 
Apoatropine 6 207-906-7 C17H21NO2 271.36   62.0 – – – 
Hydrogen chloride 7647-01-0 HCl   36.46 -114.2    -85.1 1.49 – 
LLE 
Component 
Ammonium chloride 12125-02-9 NH4Cl 53.94 338.0 520 1.52 – 
Dichloromethane, DCM 75-09-2 CH2Cl2 84.93 -96.7 39.6 1.33 0.43 
Diethyl ether, Et2O 60-29-7 C4H10O   74.12 -116.3     34.6 0.71 0.22 
n-butyl acetate, n-BuOAc 123-86-4 C6H12O 116.16   -78.0   126.1 0.88 0.69 
Toluene 108-88-3 C7H8   92.14   -95.0   111.0 0.87 0.59 
 
For the aldol addition, conversions of 5 of 67% and 78% are attained after 8 min and 24 min, 
respectively, at 100 °C, using 6.0. equiv. formaldehyde with 1.2 equiv. NaOH (3 M aq.) added to the 
effluent of PFR-1 prior to entering PFR-2 (Bédard et al., 2016). This data is used to compare 
candidate rate law expressions for PFR-2; by plotting different functions of reagent (5 and 
formaldehyde) concentrations vs. time, coefficients of determination (R2) are estimated to determine 
the goodness of fit of candidate rate law expressions. Zero-order, first-order in limiting reagent 5 and 
overall second-order (first-order in 5, first-order in formaldehyde) rate law expressions are 
considered. The integral forms of the zero-, first- and second-order rate laws are written as eqs. 1–3, 
respectively; these give linear functions of reagent concentration vs. time from which reaction rate 
constants can be estimated. Here, C5 and CCH2O are the concentrations of 5 and formaldehyde (excess 
5 
reagent), respectively, at time τPFR; Ci,0 is the initial concentration of i and kj is the jth-order rate 
constant. 
C5 = C5,0	– k0τPFR (1)
lnቆ C5
C5,0
ቇ  = –k1τPFR (2)
lnቆC5,0CCH2O
C5CCH2O,0
ቇ  = k2൫CCH2O,0	– C5,0൯τPFR (3)
 
Functions of reagent concentrations vs. time representing candidate rate law expressions considered 
here are plotted in Fig. 5. An overall second-order (first in 5, first in formaldehyde) rate law is the 
most plausible case (R2 = 0.890), followed by a first-order rate law (R2 = 0.670), followed by a zero-
order rate law (R2 = 0.512) of the candidate rate law expressions considered here. The second-order 
rate law constant for the aldol addition reaction is estimated as k2 = 1.68 L mol-1 h-1. Greater 
availability of kinetic data for this reaction set (Fig. 3) will allow further validation of kinetic 
parameter estimation results, allow investigation of more complex candidate rate law expressions and 
allow explicit consideration of the elimination of API to 6. The dataset should be as large as possible 
(enough to establish a reliable relationship whilst considering the effects of noise). However, the 
required experimental effort (time and labour) to generate sufficiently large datasets for multiple 
reactions remains crucial in kinetic data acquisition, justifying consideration and development of 
simulation and model optimisation methods to aid such efforts (Gillespie, 2008; Grom et al., 2016); a 
recent focus on statistical methods is noted (Goh et al., 2017). Conversely, modelling via limited 
datasets can aid R&D decision-making with cost-effective experimentation (especially when 
disproving flowsheets, thereby entirely circumventing costly and laborious experimental campaigns). 
From the published data, approximately 39.2% of API formed is eliminated to 6; this is considered in 
mass balance and PFR sizing calculations to obtain process performance and equipment sizing results. 
 
 
Figure 5: Comparison of candidate rate law expressions for the aldol addition vs. experimental data. 
 
2.3.2 Plug Flow Reactor (PFR) Design 
The volume of PFR-1, VPFR1, is estimated from the required residence time required to reach 99% 
conversion of 2, τPFR1 = 3.5 min (Bédard et al., 2016) and the reactor volumetric throughput, QPFR1. 
  
VPFRi = τPFRiQPFRi (4)
 
Having established the second-order (first in 5, first in formaldehyde) rate constant, k2, for the aldol 
addition, the PFR-2 residence time required to attain a reported maximum conversion of 5, X5 = 78% 
(Bédard et al., 2016) is calculated (eq. 5). 
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Here, X5 is the conversion of 5, ΘCH2O is the molar ratio of excess (formaldehyde) to limiting 
reagent (5) and νCH2O is the stoichiometric coefficient of CH2O (= –1). The volume of PFR-2, VPFR2, is 
then estimated from the residence time (τPFR2) and the reactor volumetric throughput, QPFR2, as per eq. 
4. 
 
2.3.3 Separation Process Design 
Batch (BX-) and continuous (CPM)-LLE configurations are compared for their operational and 
economical performances following the API continuous flow synthesis considered in this work 
(Bédard et al., 2016). Description of the experimentally demonstrated BX-LLE is provided in section 
2.3.3.1; conceptual CPM-LLE processes modelled in this work are described in section 2.3.3.2.  
For both BX- and CPM-LLE considerations, process performances at multiple plant API capacities, 
QAPI = {103, 104} kg API yr-1, are compared; this is useful in theoretical modelling studies in the early 
stages of process development to elucidate process performance on different operating scales (Jolliffe 
and Gerogiorgis, 2016). We also consider different assumptions of attainable solvent recovery, SR = 
{30, 50, 70}%; solvent constitutes a major contribution of material in the CPM process considered 
here, and thus differences in attainable solvent recovery are an important design consideration. 
 
2.3.3.1 Batch Liquid-Liquid Extraction (BX-LLE) 
The flowsheet for the BX-LLE process described in the literature (Bédard et al., 2016) is shown in 
Fig. 6; the process is implemented following the continuous flow synthesis process described 
previously (flowsheet provided in Fig. 4). The PFR-2 effluent is altered to pH = 6.5 with a NH4Cl 
buffer solution (aq.) with diethyl ether (Et2O) as LLE solvent; under these conditions, impurities 5 and 
6 partition in the organic phase (waste) while API and 2 remain in the aqueous phase. The aqueous 
phase of this process then undergoes an additional extraction using dichloromethane (DCM) at pH = 
10, where API selectively partitions into an organic (product) phase and 2 remains in the aqueous 
(waste) phase. The BX-LLE process attains a reported API recovery of 99% (Bédard et al., 2016). 
The considered BX-LLE process includes all essential reported purification steps as reported in the 
literature, but not considering steps associated with LLE phase solute content monitoring and 
characterisation; this is to ensure as uniform a comparison between BX-LLE and CPM-LLE processes 
as possible. 
 
 
Figure 6: Batch liquid-liquid extraction (BX-LLE) flowsheet based on the experimental 
demonstration (Bédard et al., 2016). 
 
2.3.3.1 Continuous Liquid-Liquid Extraction (CPM-LLE) Design Configurations 
The design of a continuous purification and separation processes is essential to realise the benefits of 
fully end-to-end CPM. The experimental API continuous flow synthesis demonstration described a 
possible continuous separation in which the PFR-2 effluent is altered to pH = 6.5 and toluene is added 
7 
as a LLE solvent to induce phase splitting (Bédard et al., 2016). The resulting mixture is passed 
through a packed bed (containing either sand or stainless steel beads) and a subsequent Zaiput 
membrane separator to yield an aqueous (product) phase rich in API with residual 2 from reaction 1 
and an organic (waste) phase rich in impurities 5 and 6. Modelling of flow characteristics and scaling 
of the packed bed is not possible from published data and performance of the implemented membrane 
separator is unknown (Bédard et al., 2016). Furthermore, the feasibility of implementing of packed 
beds and the described membrane separator on larger production scales is not certain. Therefore, we 
have explored an alternative conceptual continuous LLE (CPM-LLE) for comparison with the 
described BX-LLE.  
 
 
Figure 7: Conceptual continuous liquid-liquid extraction (CPM-LLE). 
 
We consider a conceptual CPM-LLE for the purification of the aqueous PFR-2 effluent under 
neutral conditions (pH = 7); the flowsheet for the continuous LLE modelled in this work is shown in 
Fig. 7. The effluent of PFR-2 is neutralised using 3 M HCl (aq.) solution. A candidate LLE solvent is 
added to the mixture to induce phase splitting. The LLE phases are then separated, producing an 
aqueous phase rich in API and residual 2 and an organic phase containing impurities (waste). 
Modelling of candidate CPM-LLE designs requires liquid-liquid equilibria data for the solvent 
system DMF + H2O + LLE solvent and an estimation of partitioning behaviour of various solutes 
(API + impurities) between LLE phases. The LLE solvents considered for implementation in this 
work are diethyl ether (Et2O), n-butyl acetate (n-BuOAc) and toluene; the shortlisting of these 
solvents for their liquid-liquid equilibria characteristics and availability of solute partitioning data in 
these solvent systems are discussed further in sections 2.3.3.3 and 2.3.3.4, respectively. 
 
2.3.3.3 Ternary Phase Compositions and Solute Partitioning 
Candidate CPM-LLE solvents must have a high propensity to form multiphase mixtures; diethyl ether 
(Et2O), n-butyl acetate (n-BuOAc) and toluene exhibit rapid phase splitting in a wide range of 
operating regions upon addition to the aqueous PFR-2 effluent (DMF + H2O) mixture. Estimation of 
LLE phase compositions are required for calculation of LLE phase properties (densities, viscosities, 
surface tensions) for LLE efficiency estimation (described in section 2.3.3.4). The popular UNIFAC 
model is used for the calculation of liquid-liquid equilibria phase compositions of different LLE 
solvent systems (Fredenslund, Jones and Prausnitz, 1975). Ternary phase diagrams for different LLE 
solvent systems of are illustrated in Fig. 8. Varying the LLE solvent-to-feed ratio (r, mass basis) 
affects resulting phase compositions, quantities and physical properties that subsequently affect LLE 
efficiency. 
To avoid explicit phase composition calculation via the UNIFAC model in the problem formulation 
(which would considerably increase computational effort), extensive preparatory UNIFAC 
simulations have been performed. Eq. 6 is an empirical polynomial to express the mole fraction of 
each component calculated via the UNIFAC model for both organic and aqueous phases of the ternary 
8 
solvent system as a function of the solvent-to-feed ratio (r), for which R2 > 0.96. Coefficients for eq. 6 
(listed in Table 2) have been estimated via nonlinear regression for estimation of phase compositions 
required for continuous LLE modelling. 
 
Figure 8: UNIFAC-modelled ternary phase diagrams of the system DMF + H2O + LLE Solvent (S) 
with example operating points (LLE solvent-to-feed ratios, r). 
 
xiS
j 	=	αiSj r2	+	βiSj r	+	γiSj  (6)
 
Here, xisj is the mole fraction of component i in phase j for solvent system DMF + H2O + LLE solvent 
(S). Table 2 provides coefficient values for eq. 6 for each solvent system, solvent component and 
phase. 
 
Table 2: Coefficients for eq. 6 estimating ternary phase compositions of the system DMF + H2O + LLE solvent 
(S) based upon extensive UNIFAC modelling. 
LLE Solvent (S) Et2O n-BuOAc Toluene 
Phase Component α β γ α β γ α β γ 
Org. 
DMF   5.50·10-3 -4.66·10-2  1.11·10-1 -9.00·10-4 -5.10·10-4 7.78·10-2  2.90·10-3 -2.37·10-2 8.57·10-2
H2O   1.80·10-3 -1.70·10-2  9.05·10-2  4.40·10-3 -3.44·10-2 1.76·10-1  3.00·10-5 -2.00·10-4 6.00·10-4
S -7.20·10-3  6.36·10-2  7.98·10-1 -3.60·10-3  3.96·10-2 7.46·10-1 -2.90·10-3  2.39·10-2 9.14·10-2
Aq. 
DMF   3.50·10-3 -3.20·10-3 -3.00·10-4  1.40·10-3 -1.35·10-2 5.14·10-2  9.00·10-4 -1.01·10-2 4.75·10-2
H2O -2.79·10-2  2.54·10-2  2.50·10-3 -4.00·10-4  9.10·10-3 9.43·10-3 -1.10·10-3  1.11·10-2 9.47·10-1
S   6.18·10-2  9.21·10-1  1.71·10-2 -1.10·10-3  4.40·10-3 5.50·10-3  2.00·10-4 -1.00·10-3 5.20·10-3
 
2.3.3.3 Solute Partitioning in Multiphase LLE Mixtures 
Estimation of API and impurities partitioning between organic and aqueous phases is required for the 
modelling of CPM-LLE of atropine. Partition coefficients of API, 2, 5 and 6 in different combinations 
of LLE solvent + H2O systems at pH = 7 and TLLE = 25 °C based upon extensive SPARC simulations 
are available in the literature (Bédard et al., 2016). For all CPM-LLE solvent systems, operation at pH 
= 7 is chosen, for which published partition coefficients for API and 2, 5 and 6 are provided in Table 
3. It is assumed that polar components NaOH and NaCl (byproduct from neutralisation of 4 by 
NaOH) remain in the aqueous phase, whereas 3 and formaldehyde are assumed to partition 
completely into the organic phase. Provision of partition coefficient data for those species not listed in 
Table 3 will allow more accurate estimation of solute component content of LLE phases required for 
process development of subsequent downstream unit operations. 
 
Table 3: Partition coefficients of API and impurities 2, 5 and 6 in different solvent systems (S) at pH 
= 7 based upon published SPARC-derived values (Bédard et al., 2016). 
Component S = Et2O S = n-BuOAc S = Toluene 
API 0.326 0.359 0.273 
Tropine 2 0.028 0.027 0.021 
Tropine Ester 5 2.054 2.312 2.598 
Apoatropine 6 2.054 3.043 3.486 
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Component partitioning of API and impurities 2, 5 and 6 are based upon partition coefficient data 
assuming pure organic (LLE solvent) and aqueous (water) phases (Bédard et al., 2016). Real LLE 
phases are not pure components, but multicomponent solvent mixtures, including DMF carrier 
solvent, and various solutes (API, impurities, other reagents). The presence of DMF and other 
components are not considered to affect the partition coefficient data used to estimate solute 
partitioning; consideration of these effects require partition coefficient data in multicomponent 
mixtures, which is not available. Investigation into the effect of additional component presence on 
solute partitioning will further elucidate the performance of different LLE designs. 
 
2.3.3.4 Continuous (CPM)-LLE Efficiency and Mass Transfer Correlations 
Estimation of LLE efficiencies from appropriate mass transfer correlations is required for 
consideration of the effect of inefficiencies associated with steady-state (continuous) operation on 
component partitioning at equilibrium. The LLE efficiency, ELLE, is calculated by eq. 7. 
 
ELLE = 
1
QLLE
KiaiVLLE
 + 1
 (7)
 
Here, Ki is the overall mass transfer coefficient, QLLE is the LLE volumetric throughput, a is the 
interfacial area between phases, and VLLE is the LLE tank volume. Ki is calculated from continuous 
and dispersed phase mass transfer coefficients, kc and kd, respectively, which are calculated by phase 
Sherwood numbers, Shi (Skelland and Moeti, 1990). 
 
K = 
1
1
kc
 + 1kd
 (8)
 Shd = 
kdd32
DAPI,d
 = 6.6 (9)
	Shc = kcd32DAPI,c  = 1.27×10
-5Scc1/3Frc5/12Eo5/4ϕ-1/2Rei2/3 ൬
di
d32
൰
2
൬d32
dt
൰
1/2
  (10)
 
Here, d32 is the Sauter mean droplet diameter, DAPI,i is the API molecular diffusivity in phase i (eq. 
11), Scc is the continuous phase Schmidt number (eq. 12), Frc is the continuous phase Froude number 
(eq. 13), Eo is the Eotvos number (eq. 14), ϕ is the continuous phase volume fraction, Rei is the LLE 
tank impeller Reynolds’ number (eq. 15) and di and dt are the impeller and tank inner diameters, 
respectively, assuming a tank aspect ratio of 1 and a tank-to-impeller diameter ratio of 2. 
 
DAPI,i = 
kbTLLE
6πμirAPI
 (11)
Scc = 
μc
ρcDAPI,c
 (12)
Frc = 
diNi2
g
 (13)
Eo = 
ρdd322 g
σ  
(14)
Rei = 
di
2Niρm
μm
 (15)
 
Here, kb is the Boltzmann constant, TLLE is the LLE operating temperature (25 °C), μi is the phase 
viscosity, rAPI is the API molecular radius, ρi is the density of phase i, Ni is the LLE tank impeller 
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speed (= 6 r.p.s. in this work), g is acceleration due to gravity, σ is the interphase surface tension, and 
ρm and μm are the mixture density and viscosity, respectively. The Sauter mean droplet diameter, d32 
(eq. 16) depends on the Weber number, We (eq. 17). 
 
d32 =	 ቊ0.052diWe
-0.6e4ϕ , We < 103
0.390diWe-0.6 , We > 103
 (16)
We = 
di
3Ni2ρc
σ  (17)
a = 
6ϕ
d32
 (18)
 
The Skelland-Moeti correlation implemented for LLE modelling (eqs. 9-17) are established from a 
large dataset of mass transfer coefficients in continuous agitated liquid-liquid systems with 
intermediate to high surface tensions (σ) and low dispersed phase volume fraction (ϕ). All solvent 
systems here have intermediate surface tensions. The volume fractions of dispersed phases of 
different solvent systems as a function of the LLE solvent-to-feed ratio (r) is shown in Table 4; all 
values are low to intermediate. 
 
Table 4: Dispersed phased volume fractions (ϕ) as a function of LLE solvent-to-feed ratio (r) for different solvent choices. 
S Et2O BuOAc PhMe 
r Dispersed Phase 
(Org. / Aq.) 
ϕ 
(%) 
Dispersed Phase 
(Org. / Aq.) 
ϕ 
(%) 
Dispersed Phase 
(Org. / Aq.) 
ϕ 
(%) 
0.25 Org. 26.06 Org. 26.30 Org. 24.57 
1 Aq. 37.74 Aq. 38.29 Aq. 42.76 
2 Aq. 22.16 Aq. 21.95 Aq. 27.04 
3 Aq. 15.46 Aq. 14.74 Aq. 19.70 
4 Aq. 11.78 Aq. 10.57 Aq. 15.42 
5 Aq. 9.40 Aq. 7.59 Aq. 12.60 
 
2.3.4 Environmental Impact Analysis 
Quantities of waste produced by different designs are compared via the popular green chemistry 
metric, the environmental (E)-factor, defined as the mass ratio of waste to desired product, i.e., 
recovered API  (Sheldon, 2012). Here, mwaste is the total mass of waste, mAPI and muAPI are the mass of 
recovered and unrecovered API, respectively, muS is the mass of unrecovered solvent and mur is the 
mass of unreacted reagents. 
 
E = 
mwaste
mAPI
 = 
muAPI + muS + mur
mAPI
 (19)
 
2.3.5 Costing Methodology 
We implement an established methodology for costing pharmaceutical manufacturing processes 
(Jolliffe and Gerogiorgis, 2016). All plant designs are assumed to be constructed and operated at an 
existing pharmaceutical manufacturing site with essential auxiliary structures already in place. Annual 
operation of 8,000 hours is considered.  
Prices for equipment of similar capacities to those considered here have been sourced where 
possible; where such data is unavailable, the following cost-capacity correlation is used (Couper, 
2003). 
 
PB = f PA ൬
SB
SA
൰
n
 (20)
 
Pj is the equipment purchase cost at capacity Sj. Parameters n and f are equipment-dependent and can 
be found in the literature (Woods, 2007). Where the reference purchase cost (PA) is taken from the 
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past, chemical engineering plant cost indices (CEPCIs) are used to calculate the corresponding present 
purchase cost in the present day. All equipment capacities are scaled to account for plantwide 
inefficiencies to meet the specified plant capacity. Table 5 gives details for the purchase costs and 
scaling parameters in eq. 20 for each equipment item. 
 
 
Table 5: Equipment parameters for calculating scaled equipment purchase costs in the present day (eq. 20). 
Item Ref. Year Ref. Cost, PA 
(GBP) 
Capacity Basis Ref. Capacity, SA n f 
(%) 
Ref. 
PFR 2014 103,208 VPFRi (mL) 80.00 1.00   1.06 (Corning, 2015) 
Pump 2015        958 – – – – (ProMinent, 2015) 
Cooler 2015     3,454 – – – – (Cole-Parmer, 2015)
Mixer 2007   22,230 Power (kW) 5 0.30 10.33 (Woods, 2007) 
LLE 2007   19,500 VLLE (L) 10 0.22 10.33 (Woods, 2007) 
 
The sum of all inflation-adjusted equipment costs (PB) gives the Free-on-Board (FOB) cost. The 
Chilton method is used to calculate the battery limits installed cost (BLIC)(Couper, 2003). The 
installed equipment cost (IEC), process piping and instrumentation (PPI) and total physical plant cost 
(TPPC) are calculated from eqs. 21-23. A construction factor of 30% is added to the TPPC to 
calculate the BLIC (eq. 24) (Jolliffe and Gerogiorgis, 2016). 
 
IEC = 1.43FOB (21)
PPI = 0.42IEC (22)
TPPC = IEC + PPI (23)
BLIC = 1.3TPPC (24)
 
Working capital (WC) costs are taken as 35% and 3.5% of annual material costs scaled to meet the 
desired plant capacity (MATannual) for batch and continuous processes, respectively (Jolliffe and 
Gerogiorgis, 2016). Contingency costs (CC) are calculated as 20% of the BLIC. The sum of BLIC, 
WC and CC gives the total capital expenditure (CapEx). 
 
WC = ൜	 0.350MATannual , batch	0.035MATannual  , CPM (25)
CC = 0.2BLIC (26)
CapEx = BLIC + WC + CC (27)
 
Required material prices are sourced from various vendors and are summarised in Table 6. The 
annual utilities cost (UTILannual) is calculated as 0.96 GBP kg-1 of the process material throughput 
(mprocess); the annual waste cost (Wasteannual) is 0.35 GBP L-1 of waste produced (Jolliffe and 
Gerogiorgis, 2016). Annual operating expenditure (OpExannual) is calculated as the sum of annual 
material (MATannual), utilities (UTILannual) and waste disposal (Wasteannual). 
 
UTILannual = 0.96mprocess (28)
Wasteannual = 0.35Qwaste (29)
OpExannual = MATannual + UTILannual + Wasteannual (30)
 
Labour costs are not included in the costing methodology as considered designs are not at the 
highest of production capacities for pharmaceutical manufacturing campaigns and reported BX-LLE 
employed in experimental demonstrations did not describe the required processing time. Batch 
processes typically require significant manual intervention (Plumb, 2005) and thus labour costs are 
expected to be considerable. Optimisation of BX-LLE (with respect to batch volumes, number of LLE 
tanks and batch scheduling) is not considered here, but will help lower operating costs; however, it is 
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unlikely that BX-LLE will perform comparably with CPM-LLE designs regarding their operational 
asset efficiencies. 
The total cost of the plant designs is calculated as the sum of CapEx and the sum of inflation-
adjusted OpExannual over the plant lifetime. 
 
 Total Cost = CapEx + ෍ OpExannualሺ1 + yሻk
t = 20
k = 1
 (31)
 
 
A plant-operating lifetime of t = 20 yr and an interest rate y = 5% are considered. All CapEx is 
assumed to occur in year 0 and operation is assumed to begin in year 1. 
 
Table 6: Material prices for reagents and components used in API synthesis and batch (BX-) and continuous 
(CPM-) LLE. 
Type Material Price (GBP kg-1) Type Material Price (GBP kg-1)
Reagent 
Tropine 2 16.91  
LLE Component
HCl (aq.)  0.08 
DMF   3.15  NH4Cl (aq.)  0.60 
Phenylacetyl chloride 3   5.49  Buffer (pH 10)  0.60 
NaOH (aq.)   0.25  DCM  0.12 
Formaldehyde   1.89  Et2O  1.59 
H2O   0.60  n-BuOAc  0.86 
 Toluene 0.56 
 
2.3.6 Nonlinear Optimisation Formulation 
The aim of the optimisation problem is to minimise plantwide total costs for atropine CPM. The 
objective function (eq. 32) of the nonlinear optimisation problem is the total cost (eq. 31) with LLE 
solvent to feed ratio (r, mass basis) and LLE tank volume as decision variables, both of which affect 
LLE phase properties and efficiency (ELLE). 
 
min Total Cost (32) 
s.t.   
0.25 < r < 5 (33) 
0 < VLLE (34) 
The optimisation problem is solved in MATLAB using the built-in solver fmincon, implementing 
the (default) interior-point algorithm with tolerances of 10-6. The problem was solved for all 
individual combinations of LLE solvent = {Et2O, n-BuOAc, toluene}, plant capacity, QAPI = {103, 
104} kg API yr-1 and assumed solvent recovery, SR = {30%, 50%, 70%}, i.e. 18 problem instances, to 
avoid mixed integer problem formulations and reduce optimisation problem complexity. 
Multiple initial values for decision variables are used to ensure a unique optimal solution for each 
problem instance. Initial values for LLE tank volume (VLLE,0) and LLE solvent-to-feed ratio (r0) are 
provided in Table 7. Initial tank volumes vary with selected plant capacity to account for varying 
material throughputs. A total of 12 initial points per problem instance is considered. Unique solutions 
were attained for all problem instances for different initial values of decision variables. 
 
Table 7: Decision variable initial values for different plant capacities for atropine CPM optimisation. 
QAPI (kg API yr-1) VLLE,0 (L) r0 # initial points per problem instance
103 {50, 100, 250, 500} {1.0, 2.5, 4.0} 12 
104 {500, 1,000, 2,500, 5,000} {1.0, 2.5, 4.0} 12 
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3. Results and Discussion 
3.1 Plug Flow Reactor (PFR) Design 
Table 7 shows PFR design results corresponding to total cost minima under different assumptions of 
CPM-LLE solvent choice and plant capacity. Varying solvent recovery (SR) has little effect on 
resulting PFR volumes; SR varies only the solvent input and waste from the process, with internal 
material flows remaining roughly the same to meet a desired plant capacity for a particular LLE 
solvent choice. Therefore, average PFR volumes and lengths for all SR assumptions are shown. 
Computed PFR volumes are small for their respective capacities for all LLE solvent choices. For all 
cases, VPFR1 < VPFR2 due to the higher conversion achieved within a shorter residence time as 
demonstrated in the experimental continuous flow synthesis (Bédard et al., 2016). Reactor volumes 
are approximately an order of magnitude larger at QAPI = 104 kg API yr-1 compared to QAPI = 103 kg 
API yr-1, reflecting the similar increase in product output. For both capacities, PFR volumes are 
smallest with toluene usage as the LLE solvent, followed by Et2O and then n-BuOAc; this is due to 
the decreasing API retention in the product aqueous phase in the LLE process as characterised by the 
published values of API partition coefficient between organic and aqueous phases for the systems 
considered here (Bédard et al., 2016). 
 
Table 8: Plug flow reactor (PFR) design results for different CPM-LLE solvent implementations. 
CPM-LLE Solvent = Et2O 
QAPI (kg API yr-1) 103 104 
Reactor Temperature 
(°C) 
XA 
(%) 
VPFRi  
(mL) 
Diameter
(mm) 
Length 
(m) 
VPFRi  
(mL) 
Diameter 
(mm) 
Length
(m) 
PFR-1 100 99 159 
  5.0 8.08 
1,511 
5.0    76.94 
10.0 2.02 10.0    19.24 
20.0 0.50 20.0      4.81 
50.0 0.08 50.0     0.77 
PFR-2 100 78 256 
  5.0 13.04 
2,438 
5.0 124.15 
10.0 3.26 10.0   31.04 
20.0 0.82 20.0     7.76 
50.0 0.13 50.0     1.24 
CPM-LLE Solvent = n-BuOAc 
QAPI (kg API yr-1) 103 104 
Reactor Temperature 
(°C) 
XA 
(%) 
VPFRi  
(mL) 
Diameter
(mm) 
Length 
(m) 
VPFRi  
(mL) 
Diameter 
(mm) 
Length
(m) 
PFR-1 100 99 167 
  5.0   8.48 
1,562 
  5.0    79.57 
10.0   2.12 10.0    19.89 
20.0   0.53 20.0     4.97 
50.0   0.08 50.0     0.80 
PFR-2 100 78 269 
  5.0 13.69 
2,521 
  5.0 128.39 
10.0   3.42 10.0   32.10 
20.0   0.86 20.0     8.02 
50.0   0.14 50.0     1.28 
CPM-LLE Solvent = Toluene 
QAPI (kg API yr-1) 103 104 
Reactor Temperature 
(°C) 
XA 
(%) 
VPFRi  
(mL) 
Diameter
(mm) 
Length 
(m) 
VPFRi  
(mL) 
Diameter 
(mm) 
Length
(m) 
PFR-1 100 99 153 
  5.0   7.77 
1,447 
  5.0   73.68 
10.0   1.94 10.0   18.42 
20.0   0.49 20.0     4.61 
50.0   0.08 50.0     0.74 
PFR-2 100 78 246 
  5.0 12.53 
2,335 
  5.0 118.89 
10.0   3.13 10.0   29.72 
20.0   0.78 20.0     7.43 
50.0   0.13 50.0     1.19 
 
Table 8 also shows resulting PFR lengths for different assumptions of PFR inner diameter. 
Selection of appropriate reactor dimensions is essential to ensure adequate heat and mass transfer 
efficiencies are maintained (Zhang et al., 2017); however, while smaller inner diameters are better for 
enhanced heat and mass transfer and mixing, resulting PFR lengths must also be feasible. Reactor 
diameter ranges (5-25 mm) consistent with our previous publications (Diab and Gerogiorgis, 2017, 
2018a, Jolliffe and Gerogiorgis, 2017a, 2017b) have been selected for PFR design. At lower 
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capacities (QAPI = 103 kg API yr-1), smaller diameters (5-10 mm) are feasible, whereas higher plant 
capacities (QAPI = 104 kg API yr-1) require larger diameters to allow feasible reactor lengths. 
Minimisation of plant footprint is possible by coiling PFRs to allow more compact designs (Mascia et 
al., 2013). 
 
3.2 Continuous Liquid-Liquid Extraction (CPM-LLE) Design 
Figure 9 shows CPM-LLE tank volumes and efficiencies corresponding to total cost minima under 
different design assumptions. For both plant capacity assumptions, CPM-LLE tank volumes are 
smallest when Et2O is used as the LLE solvent, closely followed by toluene usage, with tank volumes 
for n-BuOAc usage being considerably larger. Smaller tank volumes are required for Et2O and toluene 
due to their improved retention of API in the product aqueous phase as per the published values of 
API partition coefficient between organic and aqueous phases and stronger phase splitting observed in 
the ternary solvent systems for the solvent systems (Fig. 8) considered here (Bédard et al., 2016); as 
API retention is better for these solvent systems, smaller LLE volumes are required to attain desired 
plant capacities, which is favourable for minimising total cost contributions as per the optimisation 
problem formulation. Tank volumes and LLE efficiencies decrease as the assumed solvent recovery 
increases; when more solvent is recovered, the process becomes both more materially- and 
economically-efficient (lower waste costs = lower OpEx) and thus the same plant capacity can be 
achieved by operating with smaller tanks and resulting lower LLE efficiencies. 
 
 
Figure 9: Cost optimal continuous liquid-liquid extraction (CPM-LLE) designs for different design 
assumptions. 
 
The CPM-LLE solvent-to-feed ratio (r) is pushed to the lower bound of 0.25 in all design cases. 
Addition of LLE solvent is more influential on the properties of phases, tank residence time and LLE 
efficiency than it is on retention of API in the aqueous product phase, i.e., plantwide API recovery. 
Addition of LLE solvent also affects impurity removal into the organic phase. It is likely that there 
will be a maximum impurity content allowed in the aqueous mixture prior to subsequent API 
crystallisation; quantification of such limits could be incorporated as additional constraints and allow 
recasting of the problem for multiobjective optimisation. Further knowledge of purity and processing 
requirements prior to subsequent atropine crystallisation from this aqueous stream will inform further 
CPM development. Validity of the optimal design and operating parameters presented here are for the 
stated plant capacities, solvent recoveries and LLE solvent choices; implementation of process 
analytical technology (PAT) is essential to ensure optimal process design results presented here to 
realise their cost optimal benefits for successful CPM implementation (Eldin et al., 2016; Yu and 
Kopcha, 2017). 
Designs for CPM-LLE here assume a single tank implementing the desired purification. The 
consideration of multiple LLE tanks in series with comparative evaluation of crosscurrent (suitable for 
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small scale applications) and countercurrent (economical solvent usage) flow arrangements has not 
been considered here but can further elucidate CPM benefits for atropine production. Splitting the 
PFR-2 effluent into multiple feeds for separate LLE tanks is also a possibility that would provide 
additional operational flexibility; consideration of these design variations in future work will further 
clarify potential promising operating configurations for atropine CPM. 
 
3.3 API Recoveries, E-Factors and Impurity Partitioning 
Figure 10 shows attained API recoveries and E-factors corresponding to total cost minima under 
different design assumptions. The recovery attainable when implementing BX-LLE (assumed to be 
99% for all as reported in the experimental demonstration (Bédard et al., 2016) and for all considered 
capacities and solvent recoveries) is significantly higher than those attained via CPM-LLE design 
options; however, corresponding E-factors for BX-LLE is very high for all solvent recovery options. 
For CPM-LLE designs, the highest recoveries, and correspondingly lowest E-factors, are attained 
when using Et2O, followed by toluene, followed by n-BuOAc as LLE solvent. API recoveries 
decrease with increasing solvent recovery; this shows that API recoveries do not need to be as high to 
attain desired API capacities when higher solvent recovery is attainable, i.e., the cost benefits of 
recycling solvent allow for lower recoveries. Solvent constitutes a large portion of the material 
throughput of the process; thus, higher solvent recoveries lead to substantially lower E-factors. The E-
factors for the CPM-LLE are high here due to the material intensity of the designed process, but they 
are still acceptable for pharmaceutical processes, which can have E-factors as high as 200 
(Roschangar, Sheldon and Senanayake, 2015) and present significant reductions when compared to 
BX-LLE processes. Operating CPM-LLE at a higher pH would mean less water addition via 
neutralisation is required prior to LLE, which would consequently lower the E-factor; however, safety 
and operability considerations of operating under highly alkaline conditions on large production 
scales must also be considered. 
 
 
Figure 10: API recoveries and E-factors at cost optima of different design assumptions for plants with 
batch (BX)- and continuous (CPM)-LLE. 
 
Figure 11 shows the ratio of API to impurity components (2, 5 and 6) in CPM-LLE aqueous 
product streams at attained total cost minima under different design assumptions. API constitutes 
>60% of the solute content in the aqueous product stream (excluding NaCl, NaOH and H2CO3 
present) in all cases; these are the most important solutes asides from the API, as selective 
crystallisation of API from the aqueous mixture over these impurities may be difficult in their 
presence due to their structural similarity to atropine. It is likely that there will be a maximum 
impurity content allowed in the aqueous mixture prior to subsequent API crystallisation; knowledge 
of such limits could be incorporated as additional constraints to the problem formulation. Further 
knowledge of such limits will elucidate additional cost contributions arising from further processing 
requirements, e.g., increased LLE equipment requirements and further LLE solvent addition, to clarify 
total cost components of different design configurations. 
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Figure 11: Molar ratios of API and impurities in product aqueous stream for different design 
assumptions. 
It was previously mentioned that partition coefficient data used for calculation of API and impurity 
partitioning between phases assumes that organic phases are pure LLE solvent and aqueous phases are 
pure water. Real phases are multicomponent mixtures which affect the validity of this assumption. 
From the ternary phase diagrams for different solvent systems estimated from the UNIFAC model 
(Fig. 8), organic and aqueous product phases always contain <10 mol% DMF for all solvent systems 
considered here; however, neither phase is ever pure LLE solvent/water, and so the effect of the 
assumptions made when using published partition coefficient data in this work must be considered 
when interpreting the presented optimisation results. 
 
3.4 Minimum Total Cost Components 
Figure 12 shows minimum total cost components and contributions for different design assumptions. 
OpEx components decrease as solvent recovery increases due to reduced material requirement and 
waste costs; enhancing solvent recovery is shown to significantly lower total costs due to the large 
contribution solvent content makes towards total material throughput and the large contribution of 
OpEx towards total costs. Decreasing OpEx with increasing solvent recovery assumptions is also 
illustrated by correspondingly increasing CapEx contributions. Materials and waste costs remain 
fairly consistent with varying solvent recovery, whereas utilities costs remain fairly consistent as 
internal material flows remain roughly the same in order to meet desired plant capacities. Similarly, 
CapEx components remain fairly consistent with varying solvent recovery; internal flowrates remain 
the same despite different solvent recoveries, and thus unit sizes remain approximately constant. BLIC 
dominates CapEx in all cases due to expensive CPM equipment (Table 4) while material costs 
dominate OpEx due to expensive reagents (Table 6). Total costs are approximately an order of 
magnitude higher at QAPI = 104 kg API yr-1 than at the lower QAPI = 103 kg API yr-1, reflecting the 
tenfold capacity increase. 
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Figure 12: Minimum total cost components and contributions for different design assumptions. 
 
Plant designs implementing BX-LLE are significantly higher than CPM-LLE for all design 
assumptions. CapEx components are higher due to the increase equipment requirements of BX-LLE 
compared to CPM-LLE processes (Figs. 6 and 7); OpEx components are higher due to the increased 
material requirements of BX-LLE compared to CPM-LLE. The increased material throughputs of 
BX-LLE are reflected in the high contribution of utilities to total BX-LLE costs. Table A1 (Appendix 
A) shows attained cost savings for different design assumptions (LLE solvent choice, plant capacity 
and solvent recovery) for CPM-LLE with respect to BX-LLE, which are significant for all cost 
components. The continuous LLE modelled in this work is a simplified version of the continuous 
separation implemented in the literature (Bédard et al., 2016), which could not be modelled here due 
to the lack of explicit data on the performances of the implemented packed bed and membrane 
separator for reactor effluent purification (see section 2.3.3.1, Fig. 6). Our conceptual design has not 
been demonstrated in the literature and therefore optimisation results validation vs. experimental data 
is not possible. The presented results should be corroborated with experimenal investigation for 
validation and further elucidation of optimal design configurations for continuous atropine LLE. 
Optimisation results show that toluene is the best LLE solvent choice, attaining the lowest total 
costs for all design cases presented. The next best LLE solvent is Et2O, followed by n-BuOAc. 
Further corroboration of optimisation results with experimental validation as well as solvent 
harmonisation with crystallisation and other downstream processes is essential for atropine CPM 
development. Although toluene is more economically favourable, it has less favourable EHS criteria 
compared to n-BuOAc (Alder et al., 2016). Explicit consideration of solvent selection heuristics based 
upon EHS criteria is not incorporated into the modelling and optimisation framework presented here; 
selection of LLE solvents in industrial practice will require consideration of EHS criteria as an 
integral part of the design process. 
 
4. Conclusions 
This work solves a novel nonlinear optimisation problem for the total cost minimisation of the 
continuous manufacturing of atropine, establishing promising plant designs with respect to LLE 
design and operating parameters. The implemented process model incorporates kinetic parameter 
estimation from experimental data for PFR design, UNIFAC modelling for ternary phase composition 
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and physical property estimation and published mass transfer correlations for LLE modelling and an 
established costing methodology for batch and continuous pharmaceutical processes. Optimisation of 
a conceptual continuous LLE for the purification of the API synthesis effluent following the 
continuous flow synthesis (Bédard et al., 2016) for different LLE solvent choices and design 
assumptions (plant capacity and solvent recovery) are used to elucidate promising designs for atropine 
CPM. The LLE solvent-to-feed ratio (r) is driven to the lower bound in all design cases while LLE 
tank volumes vary between different design options due to its effect on LLE efficiency (affecting 
OpEx components) and CapEx contributions. Toluene emerges as the most economically favourable 
LLE solvent choice, offering significant total cost savings over batch LLE designs with acceptable 
material efficiencies for pharmaceutical manufacturing applications. Consideration of impurity limits 
in the LLE product aqueous stream and LLE solvent selection for harmonisation with subsequent 
crystallisation processes will provide further insight into optimal process configurations for atropine 
CPM. This work demonstrates the value of conducting technoeconomic optimisation studies towards 
the development of continuous processes in pursuit of economically viable end-to-end CPM plants. 
Industrial implementation and experimental validation of such efforts remain strategic R&D priorities: 
streamlining the use of lab- and/or pilot plant-scale reaction and separation experiments to guide the 
CPM process development effort is strongly recommended, especially via first-principles plantwide 
models which (in contrast to many data-driven ones) are applicable across all plant scales and sizes. 
Evaluating economic benefits systematically is of critical industrial importance, hence systematic 
modelling efforts can catalyse an accelerated and widespread adoption of continuous manufacturing.   
 
Author Information 
Corresponding Author 
Email: D.Gerogiorgis@ed.ac.uk 
Phone: + 44 131 6517072 
ORCID ID: Dimitrios I. Gerogiorgis: 0000-0002-2210-6784 
Acknowledgements 
Mr. Samir Diab gratefully acknowledges the financial support of the Engineering and Physical 
Sciences Research Council (EPSRC) via a Doctoral Training Partnership (DTP) PhD Fellowship 
(Grant # EP/N509644/1). Mr. Nikolaos Mytis and Prof. Andreas Boudouvis gratefully acknowledge 
financial support of Erasmus+ Student and Teaching Exchange Travel Scholarships from the National 
Technical University of Athens (NTUA) to the University of Edinburgh. Dr. Dimitrios I. Gerogiorgis 
gratefully acknowledges a Royal Academy of Engineering (RAEng) Industrial Fellowshp.  
  
19 
Appendix A: Continuous LLE Total Cost Component Savings 
A cost savings comparison between CPM-LLE and BX-LLE plantwide designs is given in Table A1. 
Table A1: Total cost components (106 GBP) with batch (BX) and continuous (CPM) LLE and CPM savings (%). 
QAPI = 103 kg yr-1 
  
BX 
 CPM 
   Et2O  n-BuOAc  Toluene 
SR (%) Component  Cost  Cost Savings  Cost Savings  Cost Savings 
30 
BLIC 4.86  2.24 -53.97 2.70 -44.45  2.22 -54.35
WCC 1.05  0.45 -56.90 0.54 -48.06  0.45 -57.30
CapEx 5.91  2.69 -54.48 3.24 -45.09  2.67 -54.87
Materials   2.59  1.62 -37.51 1.52 -41.38  1.32 -48.90
Utilities   5.64  1.39 -75.38 1.46 -74.15  1.34 -76.30
Waste   3.76  0.45 -87.98 0.45 -88.00  0.41 -88.95
OpEx 11.98  3.46 -71.15 3.43 -71.41  3.07 -74.35
Total Costs 17.89  6.15 -65.65 6.67 -62.72  5.74 -67.92
50 
BLIC 4.86  2.21 -54.47 2.69 -44.77  2.20 -54.72
WCC 1.05  0.45 -56.67 0.54 -47.49  0.44 -56.94
CapEx 5.91  2.66 -54.85 3.23 -45.24  2.64 -55.11
Materials 1.94  1.31 -32.83 1.24 -36.46  1.09 -44.15
Utilities 5.64  1.20 -78.68 1.26 -77.71  1.16 -79.52
Waste 2.68  0.33 -87.86 0.32 -87.93  0.30 -88.87
OpEx 10.27  2.83 -72.40 2.82 -72.57  2.54 -75.27
Total Costs 16.17  5.49 -66.00 6.04 -62.61  5.18 -67.92
70 
BLIC 4.86  2.20 -54.82 2.65 -45.50  2.19 -55.02
WCC 1.05  0.44 -56.29 0.53 -47.30  0.44 -56.50
CapEx 5.91  2.64 -55.08 3.18 -45.81  2.63 -55.28
Materials 1.30  0.99 -24.04 0.96 -26.14  0.84 -34.97
Utilities 5.64  1.03 -81.75 1.08 -80.78  0.99 -82.48
Waste 1.61  0.20 -87.75 0.20 -87.74  0.18 -88.78
OpEx 8.55  2.21 -74.11 2.24 -73.79  2.01 -76.45
Total Costs 14.42  4.85 -66.36 5.42 -62.40  4.64 -67.83
QAPI = 104 kg yr-1 
  
BX 
 CPM 
   Et2O  n-BuOAc  Toluene 
SR (%) Component  Cost  Cost Savings  Cost Savings  Cost Savings 
30 
BLIC 47.17  16.78 -64.42 18.65 -60.45  16.32 -65.40
WCC 10.16  3.38 -66.70 3.76 -63.04  3.29 -67.66
CapEx 57.33  20.17 -64.82 22.41 -60.91  19.60 -65.80
Materials 25.88  15.49 -40.17 14.31 -44.70  12.60 -51.33
Utilities 56.40  13.29 -76.43 13.75 -75.61  12.73 -77.43
Waste 37.57  4.32 -88.49 4.25 -88.67  3.95 -89.48
OpEx 119.85  33.10 -72.38 32.32 -73.03  29.28 -75.57
Total Costs 177.18  53.27 -69.93 54.73 -69.11  48.88 -72.41
50 
BLIC 47.17  16.68 -64.63 18.58 -60.60  16.23 -65.58
WCC 9.98  3.36 -66.35 3.74 -62.55  3.26 -67.28
CapEx 57.15  20.04 -64.93 22.32 -60.94  19.50 -65.88
Materials 19.44  12.43 -36.07 11.62 -40.21  10.30 -47.01
Utilities 56.40  11.44 -79.71 11.83 -79.02  10.96 -80.57
Waste 26.83  3.10 -88.44 3.05 -88.64  2.83 -89.44
OpEx 102.67  26.97 -73.73 26.50 -74.19  24.09 -76.53
Total Costs 159.81  47.01 -70.58 48.82 -69.45  43.59 -72.72
70 
BLIC 47.17  16.61 -64.79 18.50 -60.77  16.17 -65.72
WCC 9.80  3.34 -65.93 3.72 -62.07  3.25 -66.85
CapEx 56.97  19.95 -64.99 22.22 -60.99  19.42 -65.91
Materials 12.99  9.35 -28.07 8.92 -31.31  7.98 -38.54
Utilities 56.40  9.75 -82.71 10.08 -82.13  9.34 -83.45
Waste 16.10  1.87 -88.40 1.84 -88.60  1.71 -89.40
OpEx 85.49  20.96 -75.48 20.84 -75.62  19.03 -77.74
Total Costs 142.45  40.91 -71.28 43.06 -69.77  38.44 -73.01
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Nomenclature and Acronyms 
Latin Letters and Acronyms 
a Interfacial area between LLE phases (m2 m-3) 
API Active pharmaceutical ingredient 
BLIC Battery limits installed costs (GBP) 
BX Batch 
Ci Concentration of reagent i (M) 
Ci,0 Initial concentration of reagent i (M) 
CapEx Capital expenditure (GBP) 
CC Contingency costs (GBP) 
CEPCI Chemical engineering plant cost index 
CPM Continuous pharmaceutical manufacturing 
d32 Sauter mean droplet diameter (m) 
DAPI,i API diffusivity in phase i (m2 s-1) 
di LLE tank impeller diameter (m) 
dt LLE tank inner diameter (m) 
DCM Dichloromethane 
DMF Dimethylformamide 
E Environmental (E)-factor 
ELLE LLE efficiency (%) 
Eo Eotvos number 
Et2O Diethyl ether 
f Correction factor in eq. 20 
Fr Froude number 
FOB Free-on-Board Costs (GBP) 
g Acceleration due to gravity (= 9.81 m s-2) 
IEC Installed equipment costs (GBP) 
K Overall mass transfer coefficient (m s-1) 
kj jth-order reaction rate constant (varying units) 
kb Boltzmann constant (=1.38064852 × 10-23 m2 kg s-2 K-1) 
ki Specific mass transfer coefficient of phase i (m s-1) 
LLE Liquid-liquid extraction 
mAPI Mass of recovered API (kg yr-1) 
mprocess Plant material throughput (kg yr-1) 
mur Mass of reagents remaining in waste streams (kg yr-1) 
muAPI Mass of unrecovered API (kg yr-1) 
muS Mass of unrecovered solvent (kg yr-1) 
mwaste Mass of waste (kg yr-1) 
MATannual Annual material costs (GBP yr-1) 
n Exponent in eq. 20 
Ni Impeller rotational speed (r.p.s.) 
n-BuOAc n-Butyl acetate 
OpExannual Annual operating expenditure (GBP yr-1) 
Pj Equipment purchase cost at capacity j (GBP) 
QAPI Plant API capacity (kg API yr-1) 
QLLE LLE volumetric throughput (m3 s-1) 
QPFRi Volumetric flowrate through PFR i (m3 s-1) 
Qwaste Volumetric flow of waste output (L yr-1) 
PAT Process analytical technology 
PFR Plug flow reactor 
PPI Process piping and instrumentation costs (GBP) 
r LLE solvent-to-feed ratio (mass basis) 
r0 Initial value for LLE solvent-to-feed ratio (mass basis) 
21 
R2 Coefficient of determination 
Rei LLE tank impeller Reynolds’ number 
Sj Capacity of equipment j (varying units) 
Sci Phase i Schmidt number 
Shi Phase i Sherwood number 
SR Solvent recovery (%) 
t Plant operation lifetime (yr) 
TLLE LLE operating temperature (25 °C) 
TPPC Total physical plant cost (GBP) 
UTILannual Annual utilities costs (GBP yr-1) 
VLLE LLE tank volume (m3) 
VLLE,0 Initial value for LLE tank volume (m3) 
VPFRi Volume of PFR i (m3) 
Wasteannual Annual waste disposal cost (GBP yr-1) 
WC Working capital costs (GBP) 
We Weber number 
WHO World Health Organisation 
xiSj Component i mole fraction in phase j of solvent system S 
XA Conversion of limiting reagent (%) 
y Interest rate (%) 
  
Greek Letters  
α Coefficient in eq. 6 
β Coefficient in eq. 6 
γ Coefficient in eq. 6 
Θi Molar ratio of excess reagent i to limiting reagent 
μi Viscosity of phase i (kg m-1 s-1) 
μm LLE mixture viscosity (kg m-1 s-1) 
νi Stoichiometric coefficient of reagent i 
ρi Density of phase i (kg m-3) 
ρm LLE mixture density (kg m-3) 
σ Interphase surface tension (N m-1) 
τPFRi Residence time of PFR i (s) 
ϕ Dispersed phase volume fraction 
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